Organization Profile

You just read:

Daiichi Sankyo's Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial

News provided by

Daiichi Sankyo

Nov 19, 2013, 11:50 ET